Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is on track to continue its strong financial performance with an estimated 2027 adjusted EBITDA of $151M, supported by signed contracts and strategies to offset potential growth headwinds. Management's conservative reserve load for its Highmark contract is expected to decrease as they gather more data, and they continue to see growth in commercial and Medicare segments. Despite potential challenges, such as slower than expected client signings, Evolent's strong position in the value-based care market makes it a solid investment with long-term growth potential.

Bears say

Evolent Health is facing potential risks associated with the healthcare information technology (HCIT) space, as a significant portion of its spending comes from government programs and may be affected by budget cuts or customer losses. However, with a strong performance in Q2 and a new $300 million oncology contract, the company is expected to see approximately 25% revenue growth in 2027, alleviating concerns about profitability and solidifying demand for its Performance Suite offering. Despite potential uncertainties, the company's business model and improved visibility make its shares appealing for investors.

Evolent Health (EVH) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 13 analysts, Evolent Health (EVH) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.